Abstract
Background Neurofibromatosis Type 2 (NF2) is an autosomal dominant disorder characterized by the development of multiple schwannomas, particularly at vestibular nerves, and meningiomas. The UK NF2 Genetic Severity Score (GSS) helps predicting the disease course from germline NF2 pathogenic variants, optimizing the clinical follow-up and the genetic counselling offered to affected families.
Methods Spanish Reference Center patients were classified following the GSS and patients’ clinical severity was measured and compared between GSS groups. The GSS was reviewed considering phenotype quantification, genetic variant classification and functional assays of Merlin and its downstream pathways, studied by western blot in patient’s primary fibroblast. Principal component analysis and regression models were considered to evaluate the differences between severity and NF2 germline mutations.
Results The GSS was validated in the Spanish NF2 cohort. However, for some patients harboring mutations associated to mild and moderate phenotypes, GSS did not perform as well in predicting clinical outcomes as for pathogenic variants associated to severe phenotypes. We studied the possibility of modifying the mutation classification in GSS adding functional assays to evaluate the impact of pathogenic mutations on Merlin’s function. This revision help reducing variability within NF2 mutation classes and moderately enhances the correlation between patients’ phenotype and the different prognosis parameters analyzed.
Conclusions We validated the UK NF2 GSS in a Spanish NF2 cohort although a significant phenotypic variability was identified. The revision of the GSS, named FGSS, could be an added value to the classification of mosaic patients and patients showing mild and moderate phenotypes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This works has been funding by Spanish NF lay association through 'Fundacion Proyecto Neurofibromatosis', Spanish Fundacion FEDER for Rare Disease Investigation and by the Catalonia Goverment: AGAUR 2017 SGR 496
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All procedures performed were in accordance with the ethical standards of the IGTP Institutional Review Board, who approved this study and with the 1964 Helsinki declaration and its later amendments
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Clinical and genetic data from a NF2 Spanish cohort is available.
